Lisa Porter

TL;DR: Exen atide once weekly resulted in significantly greater improvements in glycaemic control than exenatide given twice a day, with no increased risk of hypoglycaemia and similar reductions in bodyweight.

TL;DR: The goal of many clinicians who manage diabetes is to achieve optimum glucose control alongside weight loss and a minimum number of hypoglycaemic episodes, and addition of exenatide once weekly to metformin achieved this goal more often than did addition of daily doses of either sitagliptin or pioglitazone.

TL;DR: Both once daily liraglutide and once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with liratide.

TL;DR: Continuous glucagon-like peptide-1 receptor agonism with ExQW resulted in superior glycemic control, with less nausea, compared with ExBID in patients with type 2 diabetes, and both groups lost weight.

TL;DR: Exenatide QW elicited sustained improvements in glycemic control and body weight through 52 weeks of treatment and experienced further improvements in A1C and FPG, with sustained weight loss.